Analyze Your Search


  • Action links for each search result record
    • Bookmark: Allows you to Bookmark the page for easy future retrieval 
    • Email: Opens a pop-up window where you can write a message to the recipient of the email
    • Copy URL: Copies the URL of the requested document for pasting in an email or other document
    • More Info: Shows full summary of content record
  • Saved Searches and Alerts
    • Save your search for later viewing & updates by clicking the blue "Follow" button to the right of the search box. 
Targeted and Immune Therapy
  Follow Topic   Edit Search
Your search returned 32 results
from the time period: last 30 days.
Sort by Relevance / Date Group By Journal / No Grouping
Archives of pathology & laboratory medicine 
CONTEXT: - The world of oncology has changed dramatically in the past few years with the introduction of checkpoint inhibitors and immunotherapy. The promising findings of a small, phase 2 clinical trial that led to the US Food and Drug Administration breakthrough designation and approval of the anti-programmed death receptor-1 (PD-1) drug pembrolizumab (Keytruda, Merck, Kenilworth, New Jersey) to treat metastatic/refractory microsatellite instability-high colorectal cancer (CRC) has significantly boosted interest in immunomodulatory therapies in microsatellite instability-high CRC. OBJECTIVES: - To review the immune response to cancer and the role of immune checkpoints, focusing on the technical and interpretation challenges of PD-1/programmed death ligand-1 (PD-L1) testing by pathologists and the clinical implications of the test and the therapeutic potential of treating CRC with checkpoint inhibitors. DATA SOURCES: - A PubMed review was performed of articles pertaining to CRC, microsatellite instability and mismatch repair systems, molecular classification, immune response, PD-1/PD-L1, and immunotherapy. CONCLUSIONS: - Exciting success with anti-PD-1/PD-L1 and anticytotoxic T-lymphocyte-associated protein 4 (CTLA4) checkpoint inhibitors has already been reported in melanoma and in lung and renal carcinomas. Recently, microsatellite instability-high CRCs, expressing PD-L1 by immunohistochemistry, regardless of the level of that PD-L1 expression, appeared to respond to checkpoint blockades with anti-PD-1 or anti-PD-L1 agents, whereas microsatellite-stable tumors were much less responsive. With microsatellite instability routinely tested by most centers, studies that include larger cohorts are required to study the predictive role of PD-1/PD-L1 expression in microsatellite instability-high CRC, to assess which immunohistochemistry antibodies to use, to refine the scoring criteria, and to critically analyze the interpretation pitfalls.
Oncology (11)
Microsatellite Instability (8), Colorectal Neoplasms (3), Neoplasms (2), more mentions
2. Cancer Evolution during Immunotherapy.  
Date: 11/03/2017
Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.
Oncology (3)
Neoplasms (3), Melanoma (1), more mentions
Arthritis care & research 
AbstractText: Musculoskeletal manifestations of immune related adverse events (irAEs) after checkpoint inhibitor immunotherapy for cancer remain incompletely characterized and poorly understood. A recently published case series suggested that immunotherapy-induced arthritis is an aggressive process requiring high dose corticosteroids AbstractText: This was a retrospective chart review of all patients with musculoskeletal irAEs first seen by one of the authors between ...
Muscular and Skeletal Diseases (4), Oncology (3)
Arthritis (4), Neoplasms (3), Tenosynovitis (2), more mentions
The New England journal of medicine 
No summary available
Oncology (2)
Lung Neoplasms (2), more mentions
Gene Editing Provides Clues to Why Cancer Immunotherapy Often Fails..
Oncology (2)
Neoplasms (2), more mentions
Nature communications 
Abstract: Despite impressive clinical success, cancer immunotherapy based on immune checkpoint blockade remains ineffective in many patients due to tumoral resistance... TiRP tumors resist immunotherapy based on checkpoint blockade, cancer vaccines or adoptive T-cell therapy. TiRP tumors recruit and activate tumor-specific CD8(+) T cells, but these cells then undergo apoptosis.
Oncology (4), Vaccines (1)
Neoplasms (14), Melanoma (2), more mentions
Journal of the American College of Cardiology 
Abstract: Modern cancer therapy has successfully cured many cancers and converted a terminal illness ... In addition, cancer therapy can also cause myocardial damage, induce endothelial dysfunction, and alter ... the diagnosis, prevention, and management of the cardiovascular complications of cancer therapy... to work closely with cancer specialists to prevent and treat cancer therapy-induced cardiovascular complications Keyword: cancer therapy.
Oncology (11)
Neoplasms (11), Cardiomyopathies (2), Ischemia (2), more mentions
The New England journal of medicine 
... moderate-grade disease, and 17% for high-grade disease; the corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, respectively AbstractText: After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years.
Oncology (10)
Neoplasms (8), Breast Neoplasms (6), more mentions
9. Cancer biology still needs physicists.  
Date: 10/26/2017
Cancer biology still needs physicists..
Oncology (2)
Neoplasms (2), more mentions
Cancer immunotherapy: The dark side of PD-1 receptor inhibition..
Oncology (2)
Neoplasms (2), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
Purpose Fear of cancer recurrence (FCR) is prevalent, distressing, and long lasting. This study evaluated the impact of a theoretically/empirically based intervention (ConquerFear) on FCR. Methods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed treatment (not including endocrine therapy) 2 months to 5 years previously, were age > 18 years, and had scores above the clinical cutoff on the FCR Inventory (FCRI) severity subscale at screening. Participants were randomly assigned at a one-to-one ratio to either five face-to-face sessions of ConquerFear (attention training, metacognitions, acceptance/mindfulness, screening behavior, and values-based goal setting) or an attention control (Taking-it-Easy relaxation therapy). Participants completed questionnaires at baseline (T0), immediately post-therapy (T1), and 3 (T2) and 6 months (T3) later. The primary outcome was FCRI total score. Results Of 704 potentially eligible survivors from 17 sites and two online databases, 533 were contactable, of whom 222 (42%) consented; 121 were randomly assigned to intervention and 101 to control. Study arms were equivalent at baseline on all measured characteristics. ConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P < .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total). Differences in FCRI psychological distress and cancer-specific distress (total) remained significantly different at T3. Conclusion This randomized trial demonstrated efficacy of ConquerFear compared with attention control (Taking-it-Easy) in reduction of FCRI total scores immediately post-therapy and 3 and 6 months later and in many secondary outcomes immediately post-therapy. Cancer-specific distress (total) remained more improved at 3- and 6-month follow-up.
Oncology (7)
Neoplasms (5), Colorectal Neoplasms (1), Melanoma (1), more mentions
Genome medicine 
AbstractText: Next-generation sequencing (NGS) of cancer gene panels are widely applied to enable personalized cancer therapy and to identify novel oncogenic mutations AbstractText: We performed targeted NGS on 932 clinical cases of non-small-cell lung cancers (NSCLCs) using the Ion AmpliSeq™ Cancer Hotspot panel v2 assay AbstractText: Actionable ...
Oncology (10)
Neoplasms (10), Lung Neoplasms (1), more mentions
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
Participants completed assessments of QOL (Functional Assessment of Cancer Therapy-General), depressive symptoms (Patient Health Questionnaire-9), and coping (Brief COPE) at baseline and 24 weeks. We used linear regression to test intervention effects on use of coping strategies and mediation regression models with bias-corrected bootstrapping to examine whether improvements in coping mediated the effects of early palliative care ...
Oncology (6)
Neoplasms (4), more mentions
Nature medicine 
... binding was scarcely detectable in other cell types including normal integrin β7(+) lymphocytes. T cells transduced with MMG49-derived chimeric antigen receptor (CAR) exerted anti-MM effects without damaging normal hematopoietic cells. Thus, MMG49 CAR T cell therapy is promising for MM, and a receptor protein with a rare but physiologically relevant conformation can serve as a cancer immunotherapy target.
Oncology (4)
Multiple Myeloma (2), Neoplasms (2), more mentions
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 
... standard clinical and trial practices, combined with improvements in our understanding of cancer biology have resulted in the identification of a number of limitations of the ... situations reflect the consequences of prolonged control of metastatic disease using targeted therapies, thoracic oncology has generated many of the key scenarios requiring elucidation and/or improvements ...
Oncology (3)
Neoplasms (2), more mentions
The Lancet. Infectious diseases 
AbstractText: Data on carcinogenicity of human papillomavirus (HPV) types in the anus are needed to inform anal cancer prevention through vaccination and screening. This is particularly the case for people infected with HIV, who are at an increased risk of anal cancer AbstractText: We did a systematic review of studies published from January, 1986, to July, 2017, in MEDLINE, Embase ...
Oncology (13)
Anus Neoplasms (11), Infections (4), Neoplasms (2), more mentions
Science (New York, N.Y.) 
Gut microbes shape response to cancer immunotherapy..
Oncology (2)
Neoplasms (2), more mentions
Cell reports 
Therapies targeting epidermal growth factor receptor (EGFR) have variable and unpredictable responses in breast cancer. Screening triple-negative breast cancer (TNBC) patient-derived xenografts (PDXs), we identify a subset responsive to EGFR inhibition by gefitinib, which displays heterogeneous expression of wild-type EGFR. Deep single-cell RNA sequencing of 3,500 cells from an exceptional responder identified subpopulations displaying distinct biological features, where elevated EGFR expression was significantly enriched in a mesenchymal/stem-like cellular cluster. Sorted EGFR(hi) subpopulations exhibited enhanced stem-like features, including ALDH activity, sphere-forming efficiency, and tumorigenic and metastatic potential. EGFR(hi) cells gave rise to EGFR(hi) and EGFR(lo) cells in primary and metastatic tumors, demonstrating an EGFR-dependent expansion and hierarchical state transition. Similar tumorigenic EGFR(hi) subpopulations were identified in independent PDXs, where heterogeneous EGFR expression correlated with gefitinib sensitivity. This provides new understanding for an EGFR-dependent hierarchy in TNBC and for patient stratification for therapeutic intervention.
Oncology (4)
Neoplasms (4), Breast Neoplasms (4), more mentions
Proceedings of the National Academy of Sciences of the United States of America 
Abstract: Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to exhaustively characterize the immunopeptidomic landscape of epithelial ovarian ...
Oncology (5)
Ovarian Neoplasms (3), Neoplasms (2), Carcinoma (1), more mentions
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 
... associated with PD-L1 positivity, and expression of immune related genes representing about 60% of MPM, represents a candidate subtype that may respond to cancer immunotherapy AbstractText: These data suggest that 60% of MPM patients characterized by either PD-L1 expression or an inflamed status present an attractive candidate for ...
Oncology (5)
Neoplasms (7), Mesothelioma (3), more mentions
1 2  | Next Page»